New GLP-1 Receptor Agonists (Diabetes & Weight) treatments in trials

Semaglutide, Tirzepatide, Liraglutide — diabetes & weight management therapies. Track the treatments still in clinical testing and see which are closest to an FDA decision.

115Closest to approval (Phase 3)

163Mid-stage (Phase 2)

112Early stage (Phase 1)

1,959Total recruiting

In one line

1,959 glp-1 receptor agonists (diabetes & weight) trials are recruiting right now, 115 of them in Phase 3 — the stage immediately before an FDA decision.

Recruiting now

Twelve of the currently recruiting studies. Open one for a plain-English summary of who it is for and what it involves.

NCT03595267RecruitingKidney Check: Diabetes, Blood Pressure & Kidney Health Checks & Care in Indigenous Communities.SponsorUniversity of ManitobaEnrolling2,500Summary NCT07512934RecruitingAssessment of Pancreatic Dysfunction in Patients With Type 2 DiabetesSponsorWest Kazakhstan Marat Ospanov Medical UniversityEnrolling310Summary NCT06503809NARecruitingEfficacy and Safety of a Ketogenic Diet in Type 1 DiabetesSponsorWashington University School of MedicineEnrolling58Summary NCT06988306NARecruitingLifestyle Interventions to Prevent Diabetes in U.S. Home Visiting ProgramsSponsorCalifornia Polytechnic State University-San Luis ObispoEnrolling978Summary NCT04874012Phase 2RecruitingTaurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 DiabetesSponsorHospital de Clinicas de Porto AlegreEnrolling94Summary NCT06571500RecruitingGrowth Hormone Resistance of Beta-cells in People With a Family History of Type 2 DiabetesSponsorUniversity of Missouri-ColumbiaEnrolling30Summary NCT04579900NARecruitingDissecting Host-microbiome Modifiers of Type 2 Diabetes RiskSponsorLaval UniversityEnrolling40Summary NCT07790081NARecruitingIntegrating Educational Videos Into Skills-Based Nutrition Programs to Reduce Type 2 Diabetes Risk in PeelSponsorUniversity of TorontoEnrolling45Summary NCT07392437NARecruitingPrevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and Identification of Its Associated Factors.SponsorCentre Hospitalier Universitaire de NiceEnrolling290Summary NCT06374277NARecruitingPharmacy-led Transitions of Care Intervention to Improve Medication AdherenceSponsorUniversity of TennesseeEnrolling388Summary NCT07073781NARecruitingProbiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose RegulationSponsorLeeds Beckett UniversityEnrolling70Summary NCT04722900RecruitingPREG - Offspring: Investigation of Children From Mothers With and Without Gestational DiabetesSponsorUniversity Hospital TuebingenEnrolling100Summary

View all 1,959 on ClinicalTrials.gov

Already approved for this area

GLP-1 Receptor Agonists

Ozempic, Mounjaro, Wegovy, Zepbound — approved products with their NDC records and billing codes.

Open the class

Every NDC in this class

The FDA registry filtered to glp-1 receptor agonists, with packaging and 11-digit billing conversions.

Search the directory

Loading the trial explorer…